# Processes and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and Depression

> **NCT06004115** · PHASE4 · RECRUITING · sponsor: **Laureate Institute for Brain Research, Inc.** · enrollment: 165 (estimated)

## Conditions studied

- Depression, Anxiety
- Fear
- Depression
- Anxiety and Fear
- Anxiety Disorders
- Anxious Depression

## Interventions

- **DRUG:** Lorazepam
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06004115
- **Lead sponsor:** Laureate Institute for Brain Research, Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-08
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 165 (ESTIMATED)
- **Last updated:** 2025-10-31

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06004115

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06004115, "Processes and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and Depression". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06004115. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*